Diabetes is a global epidemic. The recommended goals for glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and blood pressure are achieved only in a very small minority of patients. In this supplement to Metabolic Syndrome and Related Disorders, we review the data showing that the bile acid sequestrant colesevelam lowers both HbA1c and LDL-C in patients with diabetes. These data make colesevelam an attractive therapy to get more patients to achieve their LDL-C and HbA1c goals.
Get full access to this article
View all access options for this article.
References
1.
American Diabetes Association. Standards of Medical care in diabetes—2010. Diabetes Care, 2010; 33,Suppl 1:S11–S61.
2.
GaedeP, Lund-AndersonH, ParvingHH, PedersenO. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 2008; 358:580–591.
3.
JialalI, BajajLDL. Therapy and Clinical Trials: Management of Diabetic Dyslipidemia. Curr. Opin Lipidol, 2009; 20:85–86.
4.
JialalI, AmessW. Kaur Manpreet. Management of hypertriglyceridemia in the diabetic patient. Curr Diab Rep, 2010; 10:316–320.
5.
HolmanRR, PaulSK, BethelMA, MatthewsDDR, NeilHAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359:1577–1589.
6.
CheungBM, OngKL, ChernySS, ShamPC, TsoAW, LamKS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med, 2009; 122:443–453.
7.
JialalI, AbbyS, MisirS, NagendranS. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colveselam hydrochloride in patients with type 2 diabetes: A pooled analysis. Metab Syndr Relat Disord, 2009; 3:255–258.
8.
RidkerP, DanielsonE, FonsecaF, GenestJ, GottoA, KasteleinJ, KoenigW, LibbyP, LorenzattiA, MacFaydenJ, NordesgaardB, ShepherdJ, WillersonJ, GlynnR. Reduction in C-Reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet, 2009; 373:1175–1182.
